Genmab presents "encouraging" data for cervical cancer candidate

During the annual European Society for Medical Oncology conference (ESMO), Genmab and partner have released results for the therapy tisotumab vedotin, for which the company is seeking priority review status.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR

Genmab and its partner Seagen have presented interim data from a study of the drug tisotumab vedotin in combination therapy with the treatment of recurrent or metastatic cervical cancer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading